₹1,173
▼ -15.45 -1.30%
23 Sept 2026
NSE Listed · Pharmaceuticals
ASM 1Sakar Healthcare Limited (SAKAR)
Volume: 1,37,230Avg Vol 1W: 1,16,011Avg Vol 1M: 2,02,91652W Range:₹333.5₹1,229.85
Key Ratios
Checked just nowMarket Cap₹2,635 Cr
Current Price₹1,173
Previous Close₹1,188.45
High / Low (52w)₹1,229.85 / ₹333.5
Volume1,37,230
Avg Vol (1W)1,16,011
Avg Vol (1M)2,02,916
Stock P/E73.02
Book Value₹145.82
Dividend Yield0%
ROE9.4%
ROA7.5%
Revenue (TTM)—
Revenue Growth15.8%
Profit Margin13.27%
Total Debt₹54 Cr
Shares Outstanding2 Cr
Face Value₹10
EPS (TTM)₹16.22
P/B8.12
Debt / Equity0.26
50 DMA₹957.82
200 DMA₹670.47
Day change-1.30%
SurveillanceASM 1
Price Chart
₹1,173▲ 222.47% · 1Y
2025-09-232026-09-23
20-day avg volume: 2.2L shares
Pros
- Company is almost debt-free.
Cons
- Revenue fell 71% YoY.
- Stock trades at a high P/E of 73.
Quarterly Results
| Metric | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹43 Cr | ₹43 Cr | ₹50 Cr | ₹53 Cr | ₹58 Cr | ₹70 Cr | ₹71 Cr | ₹73 Cr |
| EBITDA | ₹7 Cr | ₹7 Cr | ₹10 Cr | ₹8 Cr | ₹7 Cr | ₹13 Cr | ₹20 Cr | ₹16 Cr |
| Net Profit | ₹5 Cr | ₹5 Cr | ₹6 Cr | ₹5 Cr | ₹5 Cr | ₹10 Cr | ₹11 Cr | ₹10 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Mar 2025 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹50 Cr | ₹179 Cr | ₹53 Cr | ₹58 Cr | ₹70 Cr | ₹254 Cr | ₹71 Cr | ₹73 Cr |
| EBITDA | ₹10 Cr | ₹30 Cr | ₹8 Cr | ₹7 Cr | ₹13 Cr | ₹48 Cr | ₹20 Cr | ₹16 Cr |
| Net Profit | ₹6 Cr | ₹18 Cr | ₹5 Cr | ₹5 Cr | ₹10 Cr | ₹30 Cr | ₹11 Cr | ₹10 Cr |
| EPS | — | 7.95 | — | — | — | 13.7 | — | — |
Balance Sheet
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Total Assets | ₹115 Cr | ₹178 Cr | ₹268 Cr | ₹336 Cr | ₹389 Cr | ₹415 Cr | ₹481 Cr |
| Total Liabilities | ₹34 Cr | ₹79 Cr | ₹140 Cr | ₹163 Cr | ₹126 Cr | ₹130 Cr | ₹157 Cr |
| Equity | ₹81 Cr | ₹98 Cr | ₹127 Cr | ₹173 Cr | ₹262 Cr | ₹285 Cr | ₹324 Cr |
| Total Debt | — | — | — | — | — | — | — |
Cash Flow
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating | ₹22 Cr | ₹15 Cr | ₹36 Cr | ₹38 Cr | ₹142 Cr | ₹36 Cr | ₹53 Cr |
| Investing | ₹-22 Cr | ₹-47 Cr | ₹-90 Cr | ₹-74 Cr | ₹-52 Cr | ₹-31 Cr | ₹-28 Cr |
| Financing | ₹3 Cr | ₹32 Cr | ₹55 Cr | ₹41 Cr | ₹27 Cr | ₹-3 Cr | ₹-21 Cr |
| Free Cash Flow | ₹13 Cr | ₹4 Cr | ₹36 Cr | ₹38 Cr | ₹142 Cr | ₹36 Cr | ₹53 Cr |
Shareholding
Promoter 52.52% Institutions 23.51% Public 23.98%
Efficiency & Working Capital
ROCE12.5%
Interest Coverage6.1
Dividend Payout—
Debtor Days73 d
Inventory Days102 d
Payable Days75 d
Cash Conversion Cycle99 d
Working Capital Days174 d
Shareholding Details
As of 2026-06-30
Promoter52.5%
FII12.1%
DII11.4%
Institutions23.5%
Public24%
Promoter Pledge0%
No. of Shareholders14,734
Shareholding Pattern
Quarterly — figures in %. Latest 12 quarters.
| Period | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 54.2% | 53.2% | 53.2% | 53.2% | 53.2% | 53.6% | 53.6% | 52.9% | 52.9% | 52.9% | 52.9% | 52.5% |
| FIIs | 14% | 13.8% | 13.5% | 13.5% | 13.4% | 13.6% | 13.6% | 13.4% | 13.3% | 13% | 12.9% | 12.1% |
| DIIs | 0% | 10.6% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 11.4% | 11.3% | 11.4% |
| Public | 31.8% | 22.5% | 33.3% | 33.3% | 33.4% | 32.8% | 32.8% | 33.7% | 33.8% | 22.7% | 22.9% | 24% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 7,299 | 7,001 | 7,386 | 7,313 | 7,867 | 8,598 | 8,608 | 8,115 | 7,565 | 7,069 | 9,580 | 14,734 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202603 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Sanjay S Shah | Shareholding of Promoter and Promoter Group | 45% | 1.00 Cr |
| Tata Capital Healthcare Fund Ii | Public Shareholding | 10.4% | 23,09,910 |
| Hbm Healthcare Investments (cayman) Ltd | Public Shareholding | 6.7% | 15,00,000 |
| Shah Aarsh | Shareholding of Promoter and Promoter Group | 6.3% | 14,07,500 |
| Cobra India (mauritius) Limited | Public Shareholding | 3.9% | 8,75,780 |
| Ritaben Shah | Shareholding of Promoter and Promoter Group | 1.1% | 2,45,000 |
| Shah Ayushi | Shareholding of Promoter and Promoter Group | 0.1% | 24,000 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| Sanjay S Shah. | Chairman & Managing Director | 2025 |
| Aarsh S Shah | Joint Managing Director | 2025 |
| Visalakshi Chandramouli | Non-Exec & Non-Independent Dir | 2025 |
| JIGNESH MUKUNDBHAI PARIKH | Independent Non Exe. Director | 2025 |
| Khyati B. Shah | Independent Non Exe. Director | 2025 |
| Sunil Marathe | Whole Time Director- Technical | 2025 |
| Megha Kamal Samdani | Independent Non Exe. Director | 2025 |
| Reeya Kothari | Independent Non Exe. Director | 2025 |
| Hiral Vinodbhai Patel | Independent Non Exe. Director | 2025 |
| Bharat Soni | Company Sec. & Compli. Officer | 2025 |
Segments — Product
| Segment | Revenue | Share |
|---|---|---|
| Manufacturing of Pharmaceutical pro | ₹0 Cr | — |
Segments — Geography
| Region | Revenue | Share |
|---|---|---|
| Domestic | ₹100 Cr | 39.9% |
| Export | ₹151 Cr | 60.1% |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2026 | ₹10 | 25 | 22 | 22 |
Corporate Actions
| Type | Date | Value | Remark |
|---|---|---|---|
| forthcoming | 2026-07-24 | Board Meetings | — |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 0 | 0 | 0 | 4 | 0 | 4 |
| 2025 | 0 | 0 | 0 | 3 | 0 | 3 |
| 2025 | 0 | 0 | 0 | 2 | 0 | 2 |
Company Information
🌐 www.sakarhealthcare.com ↗
📍 10/13 Nr MN Desai Petrol Pump, Sarkhej Bavla Highway, Changodar, Gujarat, 382213
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search